PharmaSens announced today that it appointed Dr. Robert A. Gabbay and James L. Peterson to its board of directors.

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

As part of National Diabetes Awareness Month, the Children's Diabetes Foundation is encouraging Type 1 diabetics to post on ...

Insulet raised its annual revenue growth forecast on Thursday, banking on strong demand for its wearable insulin pumps. Shares of the medical device maker rose about 2.5% to $251 in extended trading.

Analyst Jeff Johnson from Robert W. Baird maintained a Buy rating on Insulet (PODD – Research Report) and keeping the price target at ...

Katie Sullivan, DNP, FNP-C, is publicizing her own challenge with updating an insulin pump as part of an effort to bring an end to the biannual seasonal clock changes in the United States.

The rising popularity of the continuous glucose monitor, which is not the same as an insulin pump, has been a huge advance in ...

PharmaSens, a developer of insulin patch pumps for people with diabetes, has appointed Robert A. Gabbay, MD, PhD, FACP and James L. Peterson to its board of directors.

The U.S. Food and Drug Administration on Thursday announced a Class 1 recall for Medtronic MiniMed 600- and 700-series insulin pumps because of an increased risk of shorter battery life that could ...

as well as specialty pumps such as insulin, patient-controlled analgesia, enteral, and implantable infusion pumps. The report focuses on application areas such as diabetes management, pain ...

PORTLAND, GA, UNITED STATES, November 5, 2024 /EINPresswire / -- The global Implantable Insulin Pump Market was pegged at $2.67 billion in 2020, and is estimated to reach $6.44 billion by 2030, ...

Tandem Diabetes Care (TNDM) and Insulet (PODD) stocks draw outperform ratings at Bernstein as insulin pump makers prepare for ...